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HLA-matched sibling donor (MSD) stem cell transplantation can cure.60% of pediatric patients with acute
lymphoblastic leukemia (ALL), but \30% of patients will have a sibling donor. Alternative donor (AD)
transplantation can be curative but has a higher risk of graft-versus-host disease (GVHD). The addition of
alemtuzumab (Campath 1-H) to AD transplants produces in vivo T cell depletion, which may reduce the
risk for GVHD. We now report the outcome for 83 children with ALL (41 MSD, 42 AD) undergoing
stem cell transplantation in first or second complete remission. All patients received myeloablative condi-
tioning, including cyclophosphamide, cytarabine arabinoside, and total-body irradiation, with alemtuzumab
administered to AD recipients. GVHD prophylaxis consisted of a calcineurin inhibitor with either short-
course methotrexate or prednisone. Disease-free survival (DFS) for MSD recipients was 72.3% (95%
confidence interval [CI], 55.4%-83.6%) versus 62.4% (95% CI, 45.2%-75.4%) for AD recipients. The 100-
day mortality was 7.1% in the AD group and 2.4% in the MSD group. Relapse rates were identical (24%).
Treatment-related mortality, principally viral infection, explained the difference in survival. For children
undergoing stem cell transplantation (SCT) from alternative donors, alemtuzumab with a myeloablative con-
ditioning regimen resulted in DFS comparable to MSD.
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relapseINTRODUCTION
Approximately 80% of cases of acute lymphoblastic
leukemia (ALL) in children are cured using conven-
tional chemotherapy [1,2]. However, patients with
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or those who fail to attain remission after induction
chemotherapy, may obtain superior disease-free sur-
vival (DFS) if they receive matched sibling donor
(MSD) hematopoietic stem cell transplantation (SCT)
in first complete remission (CR1) [3,4]. Children who
relapse and subsequently achieve a second complete re-
mission (CR2) are unlikely to be cured with additional
chemotherapy alone [5], and matched sibling donor
SCT is the treatment of choice, producing 50% long-
term survivors in ALL in CR2. Unfortunately, most
children needing SCTwill lack a suitable sibling donor,
and so require alternative donor (AD) transplantation,
which historically has been associated with lower
overall survival (OS) (36% long-term survival fromNa-
tional Marrow Donor Program [NMDP] registry data)
[6]. The risk for treatment-related mortality (TRM)1245
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related donor transplants, but relapse rates appear to be
lower, perhaps because of an increased graft-versus-leu-
kemia (GVL) effect [7,8].
To lower rates of GVHD and facilitate engraft-
ment, we included the lymphocyte depleting antibody
Campath 1-H (alemtuzumab) in the ablative condition-
ing regimens for AD SCT. As a monoclonal antibody
targeting the CD52 antigen, alemtuzumab effectively
depletes T and B cells in vivo [9-12]. Its long half-life
also allows depletion of donor T cells, thereby reducing
the risk of GVHD [12]. In this paper, we report our ex-
perience with alternative donor transplantation using
alemtuzumab in children with acute lymphoblastic leu-
kemia in first or second complete remission.
PATIENTS, MATERIALS, AND METHODS
Patients
Weobtained institutional review board approval to
conduct this retrospective analysis. Beginning in Janu-
ary 1998, children\21 years of age with ALL in CR1
or CR2 with an HLA-matched sibling donor received
a uniform myeloablative conditioning regimen. Since
January 2001, children with ALL in CR1 or CR2 with-
out a matched sibling donor (up to 1-antigen mis-
matched related or unrelated donor) received
a uniformmyeloablative conditioning regimen that in-
cluded alemtuzumab. From January 1998 to Decem-
ber 2000, 17 children with ALL in CR1 or CR2
received an AD graft without alemtuzumab in the con-
ditioning regimen andwere excluded from the analysis.
The diagnosis of ALL was confirmed by review of
diagnostic bone marrow samples. Most children re-
ceived ALL therapy according to POG- or COG-ap-
proved studies. Patients must have achieved at least 1
CR to be included in this analysis. Remission status
was determined within 2 weeks of transplantation by
histopathological and cytogenetic analysis of marrow
and cerebrospinal fluid.
Patient Characteristics
Forty-one patients meeting the above criteria re-
ceived MSD transplants from January 1998 to August
2007. Forty-two patients received AD transplants that
included alemtuzumab in the preparative regimen
from January 2001 to August 2007. Forty-nine chil-
dren were male and 34 were female. Age range was
0.8 to 19.7 years (median5 8.5 years). Seventy-one pa-
tients had B cell phenotype and 12 had T cell pheno-
type ALL. Table 1 lists patient characteristics prior
to transplant. There was no significant difference in
clinical variables between the patient groups. Of the
AD cohort, 31 received matched unrelated donor
grafts, 9 mismatched unrelated donor grafts, and 2mismatched related donor grafts. A total of 19 patients
were transplanted in CR1, of whom 9 received MSD
and 10 received AD grafts for initial induction failure
(with subsequent remission prior to SCT), presence
of Philadelphia chromosome or hypodiploid karyo-
type. Sixty-four patients were in CR2 at the time of
SCT, with equal numbers receiving MSD and AD
grafts (32 in each group). Patients in CR2 were strati-
fied based on duration of CR1, with ‘‘early relapse’’ de-
fined as duration of CR1 less than or equal to 18
months, while ‘‘late relapse’’ was defined as duration
of CR1 greater than 18 months. Twenty-five patients
suffered early relapse, while 39 suffered late relapse.
Conditioning Regimen
Themyeloablative conditioning regimen for MSD
recipients consisted of cytarabine arabinoside 3 g/m2
Table 1. Baseline Patient Characteristics
Characteristic MSD (n 5 41) AD (n 5 42) P
Age at SCT .887*
Median 9.1 years 7.8 years
Range (1.5 to 19.7 years) (0.8 to 19.0 years)
Sex .423†
Male (%) 26 (63%) 23 (55%)
Female (%) 15 (37%) 19 (45%)
ALL phenotype .503‡
B lineage (%) 34 (83%) 37 (88%)
T lineage (%) 7 (17%) 5 (12%)
Presence of CNS disease
at diagnosis (%)
8 (20%) 5 (12%) .340‡
Infant ALL, MLL gene
rearrangement (%)
2 (5%) 2 (4%)
Remission status at SCT .840†
CR1 (%) 9 (22%) 10 (24%)
CR2 (%) 32 (78%) 32 (76%)
Time to first relapse in CR2
patients, months (range)
24.4 (4.8 to 81.1) 32.9 (3.1 to 65.4) .747§
#18 months 15 (47%) 10 (31%) .200†
>18 months 17 (53%) 22 (69%)
Time from first relapse to
BMT in CR2 patients,
days
.011*
Median 103 122
Range (46 to 474) (86 to 268)
Indications of SCT in CR1 .102‡
BCR/ABL 3 (33%) 7 (70%)
Induction failure 3 (33%) 3 (30%)
Hypodiploid 3 (33%) 0 (0%)
Sites of first relapse prior
to SCT
.302‡
BM relapse (without
CNS involvement)
11 (34%) 16 (50%)
Combined BM/CNS
relapse
7 (22%) 10 (32%)
Isolated CNS relapse 11 (34%) 5 (12%)
Other isolated
extramedullary relapse
1 (3%) 1 (3%)
MSD indicates matched sibling donor; AD, alternative donor; SCT, stem
cell transplantation; ALL, acute lymphoblastic leukemia; CNS, central
nervous system; MLL, multiple lineage leukemia; CR1, first complete re-
mission; CR2, second complete remission; BCR/ABL, breakpoint cluster
region/abelson; BM, bone marrow; NS, not statistically significant.
*Wilcoxon test.
†c2 test.
‡Fisher’s exact test.
§Log-rank test.
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phosphamide 45 mg/kg i.v. daily on days 27 and 26
with MESNA for bladder protection; total-body
irradiation (TBI) 12.0 Gy delivered in 8 fractions of
1.5 Gy on days 24 to 21. AD recipients received the
same conditioning regimen except the TBI dose was
14.0 Gy delivered in fractions of 1.75 Gy on days 24
to 21, and we included alemtuzumab (3 mg for pa-
tients 5 through 15 kg; 5 mg for patients 16 to 30 kg;
10 mg for patients greater than 30 kg) i.v. daily on
days24 to21. All male patients received an additional
4.0 Gy of irradiation to the testes. Patients with com-
bined central nervous system (CNS)/hematologic re-
lapse or isolated CNS relapse received 10.8 Gy
additional irradiation to the cranial midplane, given
in 6 fractions of 1.8 Gy daily prior to beginning the
conditioning regimen.
Stem Cell and Bone Marrow Collection
Unrelated donors were recruited through the
NMDP. DNA-based allele typing for class II DR has
been performed since 1997. Class I A and B typing
was antigen-specific until March 2005, when allele
typing was instituted. All patients received unmanipu-
lated bone marrow cells, except 2 AD recipients who
received granulocyte-colony stimulating factor
(G-CSF) mobilized CD341-selected peripheral blood
stem cells, collected according to established methods
and infused via a central venous catheter on day
0 within 24 hours of the last dose of irradiation.
GVHD Prophylaxis
Intravenous cyclosporine A was initiated at day22
and adjusted to maintain trough levels of 150-200 ng/
mL in MSD recipients; while AD recipients received
tacrolimus to maintain trough levels of 5-10 ng/mL.
All SCT recipients received short-course methotrex-
ate, except for 2 MSD and 2 AD recipients, who re-
ceived prednisone for clinical reasons. Intravenous
cyclosporine or tacrolimus was converted to oral
when the patient could tolerate medications by mouth
and was weaned off between 2 to 3 months in the
absence of GVHD. Acute and chronic GVHD
(aGVHD, cGVHD) were diagnosed according to
conventional criteria and treated according to institu-
tional guidelines. Patients were not considered evalu-
able for aGVHD if they died before engraftment or
for cGVHD if they died before day 100 after trans-
plantation.
Supportive Care and Infection Prophylaxis
All patients received bacterial, fungal, and Pneumo-
cystis jiroveci pneumonia prophylaxis during the peri-
transplant period. Monitoring of viral and fungal
infections was carried out as per our institutional stan-
dard of care. Cytomegalovirus (CMV)-seropositivepatients or those with seropositive donors received
CMV prophylaxis, most often with ganciclovir,
through day 100.
Study Endpoints
Major study endpoints were DFS, engraftment,
TRM, relapse, and frequency of aGVHD and
cGVHD. CMV infection was defined as 2 consecutive
peripheral blood polymerase chain reaction (PCR)-
positive results or antigenemia $2 leukocytes/
100,000 cells. Adenovirus infection was defined as
adenovirus PCR positivity from any source. Epstein-
Barr virus lymphoproliferative disease (EBV-LPD)
was defined as EBV viral load .4000 copies/mg in
the presence of lymphadenopathy or other clinical
manifestations [13]. Data were analyzed as of July 1,
2008.
Neutrophil engraftment was defined as the first of
3 consecutive days with an absolute neutrophil count
.500 cells/mL. Platelet engraftment was defined as
unsupported platelet count.20,000 cells/mL. Patients
were not considered evaluable for engraftment if they
died before day 30. Donor engraftment was
determined on blood and/or bone marrow using fluo-
rescence in situ hybridization probes for sex chromo-
somes (sex-mismatched transplants) or PCR
amplification of specific polymorphic DNA sequences
(short tandem repeats).
Statistical Methods
For statistical comparison between the MSD and
AD cohorts, the chi-squared test and Fisher’s exact
test were used for categorical variables and the
Wilcoxon 2-sample test for continuous variables.
Kaplan-Meier estimates and the log-rank test were
employed for the comparison of time-to-event out-
comes, including DFS following SCT, time to relapse,
and time to TRM following SCT. The analysis time
was censored administratively at 1000 days following
SCT. For the endpoint of relapse, death without re-
lapse was considered an independent competing risk.
TRMwas determined from the date of transplantation
until death related to transplantation. All P-values are
2-sided, with P\ .05 considered statistically signifi-
cant. All statistical analyses were performed using the
STATA 9.0 and SAS 9.2 software packages.
RESULTS
Table 2 outlines the post-SCT characteristics of
these transplants.
Toxicity
All patients were evaluable for toxicity. Ten pa-
tients died of treatment-related causes (nonrelapse
deaths). Although the most frequent cause of death
1248 Biol Blood Marrow Transplant 14:1245-1252, 2008A. A. Kennedy-Nasser et al.Table 2. Post-SCT Characteristics
Variable MSD (n 5 41) AD (n 5 42) P
Days to engraftment, median (range)
ANC greater than or equal to 500 cells/mL  3 days 18 (12 to 26) 18 (14 to 24) .720*
Unsupported platelets greater than 20,000 cells/mL 20 (8 to 46) 26 (11 to 130) .009*
Infections, n (%)
CMV reactivation 2 (5%) 12 (29%) .004‡
EBV-LPD 0 1 (2%)
Adenovirus reactivation 2 (5%) 14 (33%) .002‡
Invasive fungal infection 1 (2%) 3 (7%)
Bacterial sepsis 3 (7%) 3 (7%)
Acute GvHD in evaluable patients .482‡
Grade II to III 5/40 (12.5%) 3/41 (7.3%)
Grade IV 0 0
Chronic GvHD in evaluable patients .770†
Limited 8/40 (20%) 6/39 (15.4%)
Extensive 0 0
Deaths, n (%) 9 (22%) 13 (31%) .353†
Deaths due to bacterial sepsis 0 1
Deaths due to fungal disease 1 0
Deaths due to viral infection 0 6
CMV 0 2
Adenovirus 0 1
HSV 0 2
HHV6 0 1
Pulmonary toxicity/pneumonitis 1 2
Deaths due to relapse 7 5
Median time to death post transplant, days (range) 268 (54 to 3646) 147 (5 to 2187) .204§
Relapses post SCT, n (%) 9 (22%) 8 (14%) .743†
Median time to relapse, months (range) 8.8 (3.0 to 24.4) 7.4 (3.4 to 13.7)
Relapse rate
Entire cohort 23.9% (95% CI, 13.2-41.1%) 24.3% (95% CI, 12.8-43.1%) .842†
CR2 patients 27.5% (95% CI, 14.7-47.6%) 22.2% (95%CI, 10.5-43.2%) .813†
3-year disease-free survival
Entire cohort 72.3% (95%CI, 55.4-83.6%) 62.4% (95%CI, 45.2-75.4%) .232†
CR2 patients 67.9% (95%CI, 48.4-81.3%) 67.0% (95%CI, 46.9-80.7%) .777†
Early relapse (CR1 less than or equal to 18 months) 46.7% (95%CI, 21.2-68.7%) 40.0% (95%CI, 12.3-67.0%) .664†
Late relapse (CR1 greater than 18 months) 86.7% (95%CI, 56.4-96.5%) 79.5% (95%CI, 54.2-91.9%) .395†
MSD indicates matched sibling donor; AD, alternative donor; SCT, stem cell transplantation; ANC, absolute neutrophil count; CMV, cytomegalovirus;
EBV-LPD, Epstein-Barr virus lymphoproliferative disorder; BM, bone marrow; HSV, herpes simplex virus; HHV6, human herpesvirus 6; CI, confidence
interval.
*Wilcoxon test.
†c2 test.
‡Fisher’s exact test.
§Log-rank test.in the MSD cohort was relapse (78% of MSD deaths
attributable to relapse), TRM was greater in the AD
cohort (19.5% in AD versus 4.9% in MSD recipients;
P5 .045). The most common cause of TRM was pul-
monary failure or multiorgan failure attributable to
viral infections, and was limited to the AD cohort:
CMV pneumonitis (n 5 2); disseminated adenovirus
(n 5 1); herpes simplex virus pneumonitis (n52) and
human herpesvirus 6 pneumonitis (n51). Other causes
of nonrelapse death in AD recipients were idiopathic
pneumonitis (n 5 1) and sepsis (n 5 1). Only 2 MSD
recipients died of treatment-related causes, and both
failed to initially engraft: fungal disease (n5 1) and id-
iopathic pneumonitis (n 5 1).
Engraftment
Of the 83 patients, 82 were evaluable for engraft-
ment (1 AD recipient died 5 days post SCT of sepsis)
and 95% achieved neutrophil engraftment at a median
of 18 days in both cohorts (range: 12-26 in MSD and14-24 in AD). TwoMSD recipients experienced initial
graft failures, with subsequent engraftment after infu-
sion of additional CD341 cells; however, both later
died of treatment-related causes as described above.
Median time to transfusion-independent platelet
recovery was 19 days (range: 8-46) for MSD and 26
days (range: 11-130) for AD recipients (P 5 .009).
One patient failed to achieve platelet recovery before
death. No episodes of late graft failure occurred.
GVHD
The incidence and severity of aGVHD and
cGVHD was low in both cohorts. Of 40 evaluable
MSD recipients, 5 (12.5%) developed grade II to III
aGVHD, compared to 3 of 41 (7.3%) evaluable AD
recipients. No patient in either cohort developed grade
IV aGVHD. The incidence of cGVHD was low: 8 of
40 (20%) MSD recipients and 6 of 39 (15.4%) AD re-
cipients developed limited, cGVHD. Extensive,
cGVHD did not occur.
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CMV infection was more prominent in AD
recipients compared to MSD recipients (29% versus
5%; P 5 .004), an observation that is consistent with
other published reports [14,15]. Despite ganciclovir
prophylaxis, 2 patients died of CMV pneumonitis in
the AD cohort. Adenovirus infection occurred in
33% of AD recipients, including 1 death, but only
5% of MSD recipients (P 5 .002). EBV-LPD devel-
oped in 1 AD recipient and responded to treatment
with EBV-specific cytotoxic T lymphocytes generated
in our laboratory [16,17]. Respiratory viral infections
(respiratory syncytial virus and influenza A or B),
herpes simplex virus, and herpes zoster were similar
in both cohorts (data not shown). Invasive fungal infec-
tions occurred in 3 AD recipients and 1MSD recipient
(who subsequently died from fungal pneumonia). Seri-
ous bacterial sepsis occurred in 3 MSD and 3 AD re-
cipients, including 1 AD recipient with grade 4
mucositis who died at day 15 from sepsis.
Survival Analysis
Median follow-up time of all patients is 52.2
months (range: 10.6-127.2) for all patients; 77.8
months (range: 11.3-127.2) for MSD recipients, and
33.5 months (range: 10.6-78.5) for AD recipients. Be-
cause of the disparity in follow-up among MSD and
AD cohorts, patients in the MSD cohort were cen-
sored at 1000 days for Kaplan-Meier analysis. How-
ever, no patient in either cohort relapsed or died
because of a cause other than relapse beyond day
1000 post-SCT. A total of 22 patients died (9 MSD,
13 AD) at a median time of 169 days post-SCT (range:
5-1097) (Table 2). The 3-year DFS in all patients was
67.1% and comparable in both MSD and AD recipi-
ents (72.3% versus 62.4%; P 5 .232) (Figure 1). The
100-day mortality was low: 7.1% in AD recipients
and 2.4% in MSD recipients.
Patients who underwent SCT in CR2 fared identi-
cally regardless of their donor, with 3-year DFS 67.9%
for MSD and 67.0% AD (P 5 .777) (Figure 2). How-
ever, patients in CR1 trended toward improved survival
withMSD grafts: the 3-year DFS after MSD transplant
compared to AD was 87.5% and 50.0%, respectively
(P 5 .071). Of the 9 MSD recipients in CR1, 1 patient
died from relapse; of the 10 AD recipients, 3 patients
died of treatment-related causes and 2 relapsed.
Of the 64 patients in CR2, when stratified based on
time to first relapse, patients with ‘‘early relapse’’ (first
remission lasting less than 18 months) fared signifi-
cantly worse than patients whose relapse occurred
greater than 18 months after initial diagnosis (DFS
82.0% versus 44.8%, respectively; P\ .001) primarily
because of a high rate of relapse post-SCT in the ‘‘early
relapse’’ patients (Figure 3). This disparity in outcome
was seen regardless of donor source (Table 2).NineMSD and 8 AD recipients relapsed post SCT
at a median of 265 days in MSD (range: 89-731) and
221 days in AD (range: 102-441) recipients. The inci-
dence of relapse was identical (23.9% MSD versus
24.3% AD; P5 .842). The cumulative incidence of re-
lapse for MSD and AD recipients in CR2 at the time of
SCT was 27.5% and 22.2%, respectively (P 5 .813).
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Figure 1. Disease-free survival (DFS) and cumulative incidence of re-
lapse by donor source in all patients. Comparable DFS (top lines) and
incidence of relapse (bottom lines) observed in matched sibling donor
(MSD) and alternative donor (AD) recipients. The 3-year DFS for
MSD and AD recipients was 72.3% and 62.4%, respectively (P 5 .232).
The cumulative incidence of relapse for MSD and AD recipients was
23.9% and 24.3%, respectively (P 5 .842).
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Figure 2. DFS and incidence of relapse in patients in second complete
remission (CR2) at the time of transplant. Sixty-four children underwent
SCT in CR2, with comparable DFS (top lines) and incidence of relapse
(bottom lines) observed regardless of donor source. The 3-year DFS
for MSD and AD recipients in CR2 was 67.9% and 67.0%, respectively
(P 5 .777). The cumulative incidence of relapse for MSD and AD recip-
ients in CR2 was 27.5% and 22.2%, respectively (P 5 .813).
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termined by either Karnofsky or Lansky score, de-
pending on age, was equivalent in both cohorts
(mean performance score, 98.1%; range: 60%-100%
for AD and 40%-100% for MSD).
DISCUSSION
Our study illustrates that low rates of GVHD can
be achieved using alemtuzumab in alternative donor
SCT for children with ALL in first or second remis-
sion without hindering the GVL effect. Except for
TRM, the endpoints of our study, including DFS,
relapse rates, engraftment, and frequency of aGVHD
or cGVHD, were all unaffected by donor source.
Historically, high rates of GVHD and infections
following alternative donor SCT resulted in disap-
pointing outcomes for children with leukemia. How-
ever, T cell depletion has been shown to be crucial in
preventing significant GVHD following allogeneic
SCT. When the graft is not depleted of T cells, the
incidence of grades III and IV aGVHD may exceed
40% and clinically significant cGVHD may exceed
30% [18]. Although T cell depletion substantially re-
duces the incidence of aGVHD, the effect on overall
DFS is less striking, because it is also associated with
a higher ALL relapse rate. The NMDP recently re-
ported 36% 5-year DFS for 363 children with ALL
in CR2 transplanted from AD (in this case, unrelated
HLA-matched donors) [6]. Those patients receiving
T cell-depleted grafts had a significantly lower inci-
dence of aGVHD compared to recipients of non-T
cell-depleted grafts (21% versus 34%; P 5 .006) in
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Figure 3. The cumulative hazard rate of relapse based on duration of
first complete remission (CR1) — ‘‘early’’ versus ‘‘late’’ relapse. Of the
64 patients in CR2 at the time of SCT, when stratified based on ‘‘early’’
(CR1 #18 months) and ‘‘late’’ (CR1 .18 months) relapse, the cumula-
tive hazard rate of relapse post-SCT for patients with late relapse and
early relapse prior to SCTwas 11.3% and 67.1%, respectively (P\.001).univariate analysis [6]. However, T cells in the AD
graft also appear to protect against relapse [19].
Patients without aGVHD had lower 3-year DFS
than those with even mild (grades I-II) aGVHD
(32.7% versus 61.2%), and the 3-year cumulative re-
lapse rate was 55.6% versus 22% (P 5 .03) for MSD
and MUD SCT, respectively [19]. Thus, improved
DFS for MUD transplants was attributable to
a GVL effect at the expense of unwanted GVHD.
In our study, the relapse rates of MSD and AD co-
horts were identical. The low incidence of GVHD
with apparent sparing of the GVL effect in AD recip-
ients is likely attributable to in vivo T cell depletion
from alemtuzumab. Multiple studies have reported
a reduced incidence of GVHD [20-22] without rise
in relapse rates in alemtuzumab recipients [12,23].
Shah et al. [12] recently reported the effects of in
vivo alemtuzumab compared to antithymocyte globu-
lin (ATG) in unrelated donor transplants in pediatric
patients with hematologic malignancies. Rates of
GVHDwere significantly reduced in the alemtuzumab
cohort (0 of 14 compared to 6 of 13 ATG recipients;
P 5 .006) without increased relapse rates. As the ma-
jority of precursor B-ALL blasts express CD52 [24],
alemtuzumab given during the conditioning regimen
may contribute to the eradication of minimal residual
disease; thus, offering further protection against
relapse in AD SCT recipients.
Another potential explanation for GVL sparing by
alemtuzumab is the expansion of regulatory T cells
(Tregs) after transplant. Transplant recipients with
GVHD may have lower absolute numbers of donor
Tregs in the graft [25], and murine models have shown
that infusion of donor Tregs with the transplant prod-
uct or post-SCT prevents GVHD while maintaining
GVL activity [26]. Bloom et al. [27] recently reported
an increased percentage of Tregs within the CD41 T
cell population in patients receiving alemtuzumab
following renal transplant, and this increase was inde-
pendent of maintenance immunosuppression. Cur-
rently, our group is prospectively investigating the
role of alemtuzumab in promoting Treg expansion as
a mechanism for minimizing clinically significant
GVHD while sparing the GVL effect.
Although controversy has surrounded the optimal
treatment for children with recurrent ALL, duration of
CR1 has remained an important predictor of outcome
in many studies [5,6,28]. However, interpreting and
comparing these studies has proved challenging be-
cause of lack of uniformity regarding the definition
of ‘‘early relapse.’’ In our cohort of patients, early re-
lapse was defined as CR1 lasting # 18 months. Al-
though DFS was significantly lower in patients with
early relapse, it was statistically similar regardless of
donor source (ie, patients with early relapse with
MSD grafts did equally as poor as those with AD
grafts, and conversely, those with late relapse had
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tation). As pediatric ALL patients transplanted in CR2
are typically considered standard-risk patients, given
the disparity in outcomes in our study, those patients
with early relapse should probably be considered
high risk for transplant, regardless of donor source.
Thus, we contend that comparison of outcomes fol-
lowing SCT should factor the additional risk for chil-
dren with ALL and initial remission\18 months.
Two limitations of our study should be noted. First,
although the sample size of patients in each cohort is
very good, it is likely underpowered to detect all but ex-
treme differences in outcome. The second limitation is
the median follow-up time of the 2 cohorts.We recog-
nize the shorter median follow-up time in AD recipi-
ents (33 months) compared to MSD recipients (77
months); however, there were no treatment-related
deaths or relapses beyond 25 months in either cohort.
The only significant difference in outcome between
MSD and AD recipients was TRM, which was higher
in the AD cohort, likely because of the profound and
prolonged immune suppression that follows alemtuzu-
mab treatment as previously shown by our group and
others [14,15]. Compared to MSD, the AD cohort
experienced higher rates of viral reactivations and in-
fections, notably CMV and adenovirus. Six AD recipi-
ents died of viral-related infections, despite aggressive
antiviral management, prophylaxis and preemptive
treatment. Hence, better antiviral therapies are needed
to eradicate viral infections post-SCT. To this end, we
have developed methods to produce viral-specific
cytotoxic T lymphocytes against CMV, EBV, and ade-
novirus to administer following transplant [29]. As an-
tiviral treatments improve, TRM in alemtuzumab
recipients may accordingly improve; thus, greater
DFS may be achieved in alternative donor transplants
for pediatric ALL.
Our experience transplanting children with ALL
in CR1 and CR2 with alternative donors using alemtu-
zumab suggests that durable engraftment with low
rates of GVHD can be achieved, with DFS similar to
those receiving a matched sibling donor.
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